Repletion of Ergothioneine in Patients With Kidney Failure

Part of paid clinical trials in Palo Alto, California.

Sponsor
Stanford University
Study ID
NCT06487546
Status
Recruiting
Apply to this trial

Conditions

  • Esrd

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ergothioneine — DIETARY_SUPPLEMENT
    Participants will receive ergothioneine capsule daily for 12 weeks.
  • Placebo — OTHER
    Participants will receive placebo capsule daily for 12 weeks.

Study Details

Dialysis removes potentially harmful chemicals from the blood but can also remove potentially valuable chemicals. One potentially valuable chemical called ergothioneine, which comes from the diet, is low in the blood of people receiving dialysis. For this research study, the investigators hope to learn how well a daily ergothioneine supplement will replenish the levels in the blood of people with kidney failure.

Key Dates

Start date
Apr 1, 2025
Status verified
Mar 2026
Primary completion
Apr 30, 2029
Completion
Dec 31, 2030

Study Design

Enrollment
28 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Experimental: Ergothioneine
    Ergothioneine (range 5 mg to 25 mg) oral daily for up to 12 weeks
  • Placebo Comparator: Placebo
    Matching placebo oral daily for up to 12 weeks

Primary Outcome Measure

erythrocyte levels of ergothioneine [ Time Frame: weeks 1, 2, 4, 8, and 12 (while taking ergothioneine or placebo); and weeks 16 and 20 (after stopping ergothioneine or placebo) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Veterans Affairs Palo AltoPalo AltoCalifornia94304
Tammy Sirich
[email protected]
650-493-5000

Find similar trials in Palo Alto, CA

By research site
Veterans Affairs Palo Alto· Palo Alto, CA

Related Studies